Top Story

Switch to Eylea reduces fluid improves visual acuity in eyes with wet AMD

March 31, 2015

Read the Perspective from Andrew P. Schachat, MD

Fluid was reduced and visual acuity was improved in eyes with neovascular age-related macular degeneration that received Eylea after multiple intravitreal injections of Avastin or Lucentis, according to a study.

The retrospective study included 31 eyes of 31 patients with neovascular AMD who responded poorly to Lucentis (ranibizumab 0.5 mg, Genentech) and/or Avastin (bevacizumab 1.25 mg, Genentech) and were switched to Eylea (aflibercept 2 mg, Regeneron).

Evolution of the Eye: What changes might be induced in the eye with higher use of near vision?

Evolution of the Eye: What changes might be induced in the eye with higher use of near vision?

March 31, 2015
The third question included in my survey, which was sent by Ocular Surgery News Europe Edition to ophthalmology leaders worldwide, focused on changes that the intense…
thumbnail for video 4143065091001 Meeting News CoverageVideo

VIDEO: The role of posterior corneal surface in astigmatism correction during cataract surgery

March 31, 2015
John A. Hovanesian, MD, FACS, discusses a variety of techniques available to correct astigmatism.
Breaking News

IMPACT: No difference in number of injections with or without squalamine lactate for wet AMD

March 30, 2015
No meaningful difference was found in mean number of injections of squalamine lactate ophthalmic solution combined with Lucentis compared with Lucentis monotherapy for…
Breaking News

FDA accepts investigational new drug application for phase 2 trial of NT-503 encapsulated cell therapy

March 30, 2015
The FDA has accepted an investigational new drug application for a phase 2 clinical study of NT-503 encapsulated cell therapy for the treatment of recurrent subfoveal…
More News Headlines »
Practical Retina

Comparing Aflibercept, Bevacizumab, and Ranibizumab for DME: Analysis of DRCR Protocol T

Ophthalmic Surgery, Lasers and Imaging Retina
Online Advanced Release, March 5, 2015
More »
CME
Ocular Surface Disease in the Surgical Setting

Ocular Surface Disease in the Surgical Setting: Recognition and Treatment of an Increasing Dilemma

This activity is supported by an educational grant from Allergan, Inc.

Dry eye disease (DED) is becoming an increasing burden as the population ages or undergoes treatments, procedures, or…
More »
Meeting News Coverage Video
thumbnail for video 4138719116001

VIDEO: Emerging therapies for diabetic macular edema

March 30, 2015
Peter K. Kaiser, MD, highlights emerging new classes of treatment for retinal eye diseases and diabetic macular edema…
More »
morganatic-roan